Cargando…
Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma
Our group has recently demonstrated that chimeric antigen receptor T-cell therapy targeting the CD30 antigen (CD30.CAR-T) is highly effective in patients with relapsed and refractory (r/r) classical Hodgkin lymphoma (cHL). Despite high rates of clinical response, relapses and progression were observ...
Autores principales: | Voorhees, Timothy J., Zhao, Beibo, Oldan, Jorge, Hucks, George, Khandani, Amir, Dittus, Christopher, Smith, Jennifer, Morrison, J. Kaitlin, Cheng, Catherine J., Ivanova, Anastasia, Park, Steven, Shea, Thomas C., Beaven, Anne W., Dotti, Gianpietro, Serody, Jonathan, Savoldo, Barbara, Grover, Natalie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864661/ https://www.ncbi.nlm.nih.gov/pubmed/34666347 http://dx.doi.org/10.1182/bloodadvances.2021005385 |
Ejemplares similares
-
Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas
por: Tschernia, Nicholas P, et al.
Publicado: (2023) -
The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
por: Meier, Jeremy A., et al.
Publicado: (2022) -
Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL
por: Zurko, Joanna, et al.
Publicado: (2022) -
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas
por: Lynch, Ryan C., et al.
Publicado: (2022) -
Inadvertent Transfer of Murine VL30 Retrotransposons to CAR-T Cells
por: Lee, Sung Hyun, et al.
Publicado: (2022)